Latest Altium Capital Management LP Stock Portfolio
$245Million– No. of Holdings #64
Altium Capital Management LP Performance:
2024 Q2: 0.17%YTD: 16.32%2023: 0.56%
Performance for 2024 Q2 is 0.17%, and YTD is 16.32%, and 2023 is 0.56%.
About Altium Capital Management LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Altium Capital Management LP reported an equity portfolio of $245.1 Millions as of 30 Jun, 2024.
The top stock holdings of Altium Capital Management LP are VERA, ADMA, XENE. The fund has invested 10.5% of it's portfolio in VERA THERAPEUTICS INC and 6.9% of portfolio in ADMA BIOLOGICS INC.
The fund managers got completely rid off AVADEL PHARMACEUTICALS PLC (AVDL), BIOHAVEN LTD and OLEMA PHARMACEUTICALS INC (OLMA) stocks. They significantly reduced their stock positions in ACHIEVE LIFE SCIENCES INC (ACHV), AXSOME THERAPEUTICS INC (AXSM) and BOUNDLESS BIO INC. Altium Capital Management LP opened new stock positions in SAREPTA THERAPEUTICS INC (SRPT), SKYE BIOSCIENCE INC (SKYE) and ARGENX SE. The fund showed a lot of confidence in some stocks as they added substantially to ZEVRA THERAPEUTICS INC, INTRA-CELLULAR THERAPIES INC (ITCI) and INSMED INC (INSM).
The top stock holdings of Altium Capital Management LP are VERA, ADMA, XENE. The fund has invested 10.5% of it's portfolio in VERA THERAPEUTICS INC and 6.9% of portfolio in ADMA BIOLOGICS INC.
The fund managers got completely rid off AVADEL PHARMACEUTICALS PLC (AVDL), BIOHAVEN LTD and OLEMA PHARMACEUTICALS INC (OLMA) stocks. They significantly reduced their stock positions in ACHIEVE LIFE SCIENCES INC (ACHV), AXSOME THERAPEUTICS INC (AXSM) and BOUNDLESS BIO INC. Altium Capital Management LP opened new stock positions in SAREPTA THERAPEUTICS INC (SRPT), SKYE BIOSCIENCE INC (SKYE) and ARGENX SE. The fund showed a lot of confidence in some stocks as they added substantially to ZEVRA THERAPEUTICS INC, INTRA-CELLULAR THERAPIES INC (ITCI) and INSMED INC (INSM).
Altium Capital Management LP Equity Portfolio Value
Last Reported on: 15 Aug, 2024
Altium Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Altium Capital Management LP made a return of 0.17% in the last quarter. In trailing 12 months, it's portfolio return was 25.12%.
New Buys
| Ticker | $ Bought |
|---|---|
| sarepta therapeutics inc | 12,940,200 |
| skye bioscience inc | 10,814,200 |
| argenx se | 9,890,920 |
| avadel pharmaceuticals plc | 8,576,600 |
| contineum therapeutics inc | 7,560,680 |
| rezolute inc | 7,310,000 |
| moonlake immunotherapeutics | 5,056,550 |
| outlook therapeutics inc | 3,703,170 |
New stocks bought by Altium Capital Management LP
Additions
| Ticker | % Inc. |
|---|---|
| zevra therapeutics inc | 240 |
| ascendis pharma a/s | 100 |
| intra-cellular therapies inc | 70.8 |
| insmed inc | 58.33 |
| the realreal inc | 56.28 |
| quoin pharmaceuticals ltd | 55.69 |
| viking therapeutics inc | 43.53 |
| soleno therapeutics inc | 39.24 |
Additions to existing portfolio by Altium Capital Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| achieve life sciences inc | -74.11 |
| axsome therapeutics inc | -63.77 |
| boundless bio inc | -58.43 |
| biovie inc | -34.2 |
| perfect moment ltd | -31.86 |
| spruce biosciences inc | -29.46 |
| milestone pharmaceuticals in | -16.53 |
| alimera sciences inc | -15.69 |
Altium Capital Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| aquestive therapeutics inc | -2,832,900 |
| olema pharmaceuticals inc | -6,848,600 |
| avadel pharmaceuticals plc | -9,341,130 |
| perspective therapeutics inc | -637,432 |
| nocturne acquisition corp | -82,000 |
| azitra inc | -101,343 |
| mirum pharmaceuticals inc | -5,224,960 |
| gri bio inc | -142,866 |
Altium Capital Management LP got rid off the above stocks
Sector Distribution
Altium Capital Management LP has about 74.6% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 74.6 |
| Others | 23.4 |
| Consumer Cyclical | 1.9 |
Market Cap. Distribution
Altium Capital Management LP has about 10.6% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 36.5 |
| UNALLOCATED | 23.4 |
| SMALL-CAP | 14.4 |
| MICRO-CAP | 14 |
| LARGE-CAP | 10.6 |
| NANO-CAP | 1.1 |
Stocks belong to which Index?
About 43.7% of the stocks held by Altium Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 56.3 |
| RUSSELL 2000 | 43.7 |
Altium Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Altium Capital Management LP
Altium Capital Management LP has 64 stocks in it's portfolio. About 55.9% of the portfolio is in top 10 stocks. VERA proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for Altium Capital Management LP last quarter.
Last Reported on: 15 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACHV | achieve life sciences inc | 0.42 | 216,310 | 1,016,660 | reduced | -74.11 | ||
| ADMA | adma biologics inc | 6.89 | 1,510,000 | 16,881,800 | reduced | -1.95 | ||
| ALIM | alimera sciences inc | 4.88 | 2,150,000 | 11,954,000 | reduced | -15.69 | ||
| ALPN | alpine immune sciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| APDN | applied dna sciences inc | 0.01 | 86,152 | 35,184 | new | |||
| APRE | aprea therapeutics inc | 0.23 | 137,197 | 558,392 | new | |||
| AQST | aquestive therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ATXS | astria therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVDL | avadel pharmaceuticals plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AXSM | axsome therapeutics inc | 1.64 | 50,000 | 4,025,000 | reduced | -63.77 | ||
| BIVI | biovie inc | 0.32 | 198,234 | 793,928 | reduced | -34.2 | ||
| CEAD | cea industries inc | 0.00 | 250,000 | 3,750 | unchanged | 0.00 | ||
| CETX | cemtrex inc | 0.03 | 339,961 | 74,791 | new | |||
| CING | cingulate inc | 0.00 | 22,500 | 2,916 | unchanged | 0.00 | ||
| CNTX | context therapeutics inc | 0.29 | 360,001 | 721,802 | new | |||
| CPRX | catalyst pharmaceuticals inc | 3.16 | 500,000 | 7,745,000 | unchanged | 0.00 | ||
| CYBN | cybin inc | 1.54 | 13,953,500 | 3,781,400 | unchanged | 0.00 | ||
| DHAC | digital health acquisition c | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| EVOK | evoke pharma inc | 0.15 | 57,703 | 366,301 | reduced | -4.48 | ||
| FAT | fat brands inc | 0.23 | 200,000 | 569,000 | unchanged | 0.00 | ||